RxDoctor Payments Data

Genevieve Rebuffot, MD

Family Medicine · White Plains, NYNPI 1417983669

Payments from drug & device makers

$6,081in general payments, 2019–2025

Across 301 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$897
  • GSK$660
  • Amarin Pharma, Inc.$617
  • Boehringer Ingelheim$480
  • Lilly USA, LLC$473
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,081 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$29,788
Medicare patients
121
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate15$24,766
RybelsusSemaglutide17$24,324
OzempicSemaglutide20$22,391
FarxigaDapagliflozin Propanediol15$16,111
TrulicityDulaglutide13$11,805
VascepaIcosapent Ethyl23$10,701
EliquisApixaban14$9,060
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,570
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,699
Atorvastatin Calcium278$2,440
Icosapent Ethyl17$1,800
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,548
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic15$1,252
Levothyroxine Sodium100$1,102
Rosuvastatin Calcium62$949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$897$46,71537 claims
MerckJanuvia$46$24,76615 claims
AstraZenecaFarxiga$1,092$16,11115 claims
Lilly USA, LLCTrulicity$473$11,80513 claims
PfizerEliquis$287$9,06014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →